GHENT, Belgium, Aug. 19, 2015 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] will announce its half-year results for 2015 on Thursday 27 August 2015 at 7.00 am CET.
The Ablynx management team will host a conference call and webcast during which the half-year results for 2015 will be presented, followed by a Q&A session. This event will be held on Thursday 27 August 2015 at 4.00 pm CET/10.00 am EST.
The conference call will be webcast live and may be accessed under the events section of the Ablynx website or by clicking here. If you would like to participate in the Q&A session, please dial +32 (0)2 402 30 92, confirmation code 6867520. Shortly after the call, a replay of the webcast and copy of the presentation will be available under the events section of the Ablynx website.
Ablynx is a biopharmaceutical company engaged in the development of Nanobodies®, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 30 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie, Boehringer Ingelheim, Eddingpharm, Genzyme, Merck & Co., Merck Serono, Novartis and Taisho Pharmaceutical. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.
For more information, please contact
Dr Edwin Moses
t: +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
Follow us on Twitter @AblynxABLX
Ablynx media relations Instinctif Partners:
Sue Charles, Daniel Gooch
t: +44 (0)20 7866 7905
t: +32 (0)2 626 9500
pdf format of the press release http://hugin.info/137912/R/1946300/706154.pdf